Development of new therapies in primary central nervous system lymphoma

Development of new therapies in primary central nervous system lymphoma - Development of new therapies in PCNSL

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000007700

Enrollment

Registered

2012-04-09

Start date

2012-05-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Primary central nervous system lymphoma

Interventions

Arm A: treated with high-dose MTX + radiotherapy Arm B: Radiotheray alone Arm C: BSC

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: diagnosis of nonHodgkin lymphoma based on positive stereotactic or surgical biopsy, or CSF cytology; disease confined to CNS, cranial nerves, or eyes; no previous treatment; at least one measurable lesion; age 18&#8211;75 years; and adequate bone marrow, renal (creatinine clearance >75 ml min&#8722;1), cardiac, and hepatic functions.

Exclusion criteria

Exclusion criteria: positive for hepatitis B surface antigens, hepatitis C seropositivity, HIV disease or other immunodeficiencies, a Karnofsky performance score (KPS) of less than 50 for reasons not related to PCNSL, other malignant disease, and ongoing pregnancy or lactation.

Design outcomes

Primary

Measure	Time frame
overall survival	—

Secondary

Measure	Time frame
response rate and progression-free survival	—

Countries

Japan

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026